<DOC>
	<DOCNO>NCT02156648</DOCNO>
	<brief_summary>The purpose project assess feasibility collect plasma sample cardiac biomarker assessment , identify association biomarkers , echocardiographic feature cardiac PET scan result ( patient receive radiation therapy ) . This first step research program overall goal able predict early-treatment induced cardiotoxicity patient breast cancer .</brief_summary>
	<brief_title>A Feasibility Study Women Receiving Anthracycline Chemotherapy With Without Radiation HER2-neu Positive Invasive Ductal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Ductal</mesh_term>
	<criteria>1 . Stage IIII , HER2neu positive invasive ductal carcinoma 2 . Scheduled receive adjuvant/neoadjuvant 5Fluorouracil , Epirubicin , Cyclophosphamide Docetaxel ( FECD ) chemotherapy 3 . Scheduled receive adjuvant Trastuzumab 4 . ECOG Performance status 02 5 . Adequate baseline image transthoracic echocardiography , baseline cardiac ejection fraction ≥ 55 % . Additionally , breast cancer patients≥45 year age schedule receive whole breast radiation therapy receive two cardiac PET scan . 1 . Prior anthracycline chemotherapy 2 . History dilate cardiomyopathy , congestive heart failure , coronary artery disease 3 . Life expectancy le 15 month 4 . Pregnant lactate woman 5 . Use beta receptor antagonist , calcium channel antagonist , angiotensin convert enzyme inhibitor , angiotensin receptor inhibitor baseline . 6 . Previous chest wall/breast nodal radiation .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Invasive ductal</keyword>
	<keyword>HER2-neu positive</keyword>
</DOC>